This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Calamine lotion

OTC
Read time: 2 mins
Last updated: 24 Mar 2015
...
 

Summary of product characteristics


1. Name of the medicinal product

Calamine Lotion BP


2. Qualitative and quantitative composition

Active ingredients% w/v
Calamine BP 15
Zinc Oxide Ph Eur5


3. Pharmaceutical form

Lotion


4.1. Therapeutic indications

For the relief of minor skin rashes and irritation.


4.2. Posology and method of administration

Adults, children and elderly

To be applied when required to the affected area. For topical application.


4.3. Contraindications

Hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

Shake the bottle.For external use only.Keep all medicines out of the reach of children.


4.5. Interaction with other medicinal products and other forms of interaction

No clinically significant interactions known.May mask x-ray pictures under certain circumstances.


4.6. Fertility, pregnancy and lactation

The safety of Calamine Lotion during pregnancy and lactation has not been established but use during these periods is not considered to constitute a hazard.


4.7. Effects on ability to drive and use machines

No adverse effects known.


4.8. Undesirable effects

Occasional hypersensitivity or irritant reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.


4.9. Overdose

If ingested symptoms of overdosage include anorexia, nausea, vomiting, epigastric discomfort and diarrhoea. Treatment consists of symptomatic measures only.


5.1. Pharmacodynamic properties

Calamine has a mild astringent action on the skin.


5.2. Pharmacokinetic properties

None known.


5.3. Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.


6.1. List of excipients

BentoniteGlycerolSodium CitratePhenolWater Purified


6.2. Incompatibilities

None stated.


6.3. Shelf life

36 months.


6.4. Special precautions for storage

None.


6.5. Nature and contents of container

A white flint glass bottle with an unlined polypropylene cap. An amber glass bottle with vinyl seal faced compocork in thermoset plastic cap. Alternative cap: Aluminium roll-on pilfer-proof cap with a flowed in liner or a triseal (LDPE/EPE/LDPE) liner.

Pack sizes: 200, 2000 millilitres


6.6. Special precautions for disposal and other handling

None stated.


7. Marketing authorisation holder

The Boots Company PLC1 Thane Road WestNottingham NG2 3AATrading as: BCM


8. Marketing authorisation number(s)

PL 00014/5471R


9. Date of first authorisation/renewal of the authorisation

Date of First Authorisation:

31 October 1984

Date of Last Renewal:

23 January 1996


10. Date of revision of the text

16 December 2014

4.1 Therapeutic indications

For the relief of minor skin rashes and irritation.

4.2 Posology and method of administration

Adults, children and elderly

To be applied when required to the affected area. For topical application.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Shake the bottle.For external use only.Keep all medicines out of the reach of children.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant interactions known.May mask x-ray pictures under certain circumstances.

4.6 Fertility, pregnancy and lactation

The safety of Calamine Lotion during pregnancy and lactation has not been established but use during these periods is not considered to constitute a hazard.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

Occasional hypersensitivity or irritant reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).